Join us for this special episode where Deputy Editor Cheryl Lai speaks with Ali Landman, Editor-in-Chief of The Lancet Medical Imaging & Theranostics, about the scope and vision of the new journal and Ali's highlights in oncological imaging from the European Congress of Radiology in Vienna, March 4-8, 2026.

To learn more:
European Congress of Radiology: https://www.myesr.org/congress/

The Lancet Medical Imaging & Theranostics: https://www.thelancet.com/medical-imaging-theranostics

For presubmission enquiries and other questions email imaging@lancet.com

To submit your manuscript: https://www2.cloud.editorialmanager.com/thelancetimaging/default2.aspx

Join The Lancet Medical Imaging & Theranostics’ editorial team for a Lancet Webinar dedicated to helping you publish with The Lancet Medical Imaging & Theranostics https://hubs.li/Q042sbn40

Find us on LinkedIn and Bluesky @lancetimaging.bsky.social

Tell us what you thought about this episode

Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics.

You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Kayleigh Bhangdia discusses the latest GBD breast cancer study data, telling the audience about epidemiological trends, disease burden, and risk factors associated with breast cancer globally, regionally, and nationally for 204 countries from 1990 to 2023. Kayleigh sheds light on disparities in breast cancer burden across the globe and forecasts to 2050, and highlights the the most critical areas that future GBD studies should focus on to improve the accuracy, relevance, and impact of breast cancer estimates worldwide.

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00730-2/fulltext

Tell us what you thought about this episode

Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics.

You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Dr Dylan Graetz (Department of Oncology and Department of Global Pediatric Medicine, St Jude Children’s Research Hospital) and Dr Erica Kaye (Department of Oncology, St Jude Children’s Research Hospital) to discuss qualitative in oncology.

Read the full Reviews:

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00669-2 for The Power of Words: Evaluating the Role of Qualitative Methods in Cancer Research
and
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00670-9 for Expert Recommendations for the Conduct and Appraisal of Qualitative Research in Oncology

and the reviews in Lancet Haematology 2026 https://doi.org/10.1016/S2352-3026(25)00321-7
and eClinicalMedicine https://doi.org/10.1016/j.eclinm.2025.103736

Tell us what you thought about this episode

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Cheryl Lai, Senior Editor of The Lancet Oncology, is joined by Dr Jesse Plascak (Division of Cancer Prevention and Control, The Ohio State University) and Dr Marissa Baker (Department of Environmental & Occupational Health Science, University of Washington School of Public Health) to discuss their population-based study analysing cancer mortality rates by sex, cancer type, and occupation type among working-age adults in the USA.

Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00593-5/fulltext

Tell us what you thought about this episode

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Dr Andre Pfob (Department of Obstetrics & Gynecology, Heidelberg University Hospital) and Prof Peter Dubsky (Faculty of Health Sciences and Medicine, University of Lucerne) discuss their Review entitled The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer—a multidisciplinary consensus.

Click here to read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00463-2/fulltext

Tell us what you thought about this episode

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Dr Gary Rodin discusses The human crisis in cancer: a Lancet Oncology Commission which identifies a growing imbalance between technological innovation and the human dimensions of cancer care.

Click here to read the full Commission: The human crisis in cancer: a Lancet Oncology Commission

And comment: Re-establishing human-centred care

Tell us what you thought about this episode

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Deputy Editor Ali Landman speaks with Matthias Preusser (Medical University of Vienna, Vienna, Austria) about two reports from the phase 2 TUXEDO-3 trial investigating patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer or non-small-cell lung cancer.

Hear about the potential of HER3-targeted antibody-drug conjugates for brain metastases, why recruiting patients with active brain metastases to clinical trials is so important, and where the field is going next.

Click here to read the full article: Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial

Click here to read the full article: Patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial

Tell us what you thought about this episode

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Dr Andrea Necchi, Associate Professor at the Vita-Salute San Raffaele University, and the Director of Genitourinary Medical Oncology at the San Raffaele Hospital, in Milan, Italy, to discuss his SunRISe4-trial published in our October issue.

Effective treatments are needed for patients with muscle-invasive bladder cancer scheduled for radical cystectomy who are ineligible for or decline to receive neoadjuvant cisplatin-based chemotherapy. SunRISe-4 is a randomised, open-label, phase 2 trial being conducted at 109 investigative centres in ten countries worldwide, and aims to evaluate the safety and efficacy of neoadjuvant TAR-200 plus cetrelimab (anti-PD-1) versus cetrelimab monotherapy in this disease setting.

They discuss the unique features of the TAR-200 localised sustained delivery system for gemcitabine, the key findings from the SunRISe4-trial trial, and what the future implications of the findings are in terms of better treatment options for patients with bladder cancer.

Read the full article:

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00358-4/abstract?dgcid=buzzsprout_icw_podcast_September_25_lanonc

Tell us what you thought about this episode

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv